BEACON Cohort 8 & Cohort 9 Internal Investigation Concluded (GlobeNewswire) - Dec 2, 2025 - "In response, Jasper's internal investigation included: switching all US patients to a new lot of drug product for the remainder of their doses on study to determine if drug product played a role,
a comprehensive review of all manufacturing records, drug handling, site training/ logs and data handling; recovery and testing by Jasper and independent labs of drug product samples from across the supply chain; a review of all US sites and all US patients, including protocol adherence patient medical histories, patient screening and all pharmacokinetics, pharmacodynamics and efficacy data, and assembling a KOL panel to review the internal investigation findings, including full patient dossiers, which provided its input and conclusions from the findings....'BEACON data expected in Q1 2026 that will enable us to select final doses for the Phase 2b CSU study, planned to commence mid-2026.'"
New P2b trial • P1/2 data • Trial status • Chronic Spontaneous Urticaria
|